Cormorant Asset Management, LP - 28 Jun 2021 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role: Former 10% Owner
Signature: /s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP, By: Cormorant Global Healthcare GP, LLC, its General Partner By: Bihua Chen, Managing Member
Issuer symbol: GLUE
Transactions as of: 28 Jun 2021
Net transactions value: +$11,400,000
Form type: 4
Filing time: 30 Jun 2021, 16:08:35 UTC
Previous filing: 24 Jun 2021
Next filing: 01 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GLUE	Common Stock	Conversion of derivative security		+2,602,200			2,602,200	28 Jun 2021	See Footnotes	F1, F2, F3
transaction	GLUE	Common Stock	Purchase	$11,400,000	+600,000	+23%	$19.00	3,202,200	28 Jun 2021	See Footnotes	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GLUE	Series B Convertible Preferred Stock	Conversion of derivative security		+2,124,343			0	28 Jun 2021	Common Stock	2,124,343		See Footnotes	F1, F2, F5
transaction	GLUE	Series C Convertible Preferred Stock	Conversion of derivative security		+477,857			0	28 Jun 2021	Common Stock	477,857		See Footnotes	F1, F2, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Cormorant Asset Management, LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Shares of Series B and Series C Convertible Preferred Stock were convertible at any time at the holder's election, without payment of additional consideration. Such shares had no expiration date but converted into Common Stock automatically upon the closing of the Issuer's initial public offering.
F2	Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund II, Fund III, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F3	Represents (i) 330,892 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, (iii) 1,419,249 shares of Common Stock held by Fund III, and (iv) 8,482 shares of Common Stock held by the Account.
F4	Shares reported herein as purchased on June 28, 2021 represent 600,000 shares purchased by the Master Fund.
F5	The Series B Convertible Preferred Stock represented, on an as-converted basis, (i) 226,242 shares of Common Stock held by the Master Fund, (ii) 843,577 shares of Common Stock held by Fund II, and (iii) 1,054,524 shares of Common Stock held by Fund III.
F6	The Series C Convertible Preferred Stock represented, on an as-converted basis, (i) 104,650 shares of Common Stock held by the Master Fund, (ii) 364,725 shares of Common Stock held by Fund III, and (iii) 8,482 shares of Common Stock held by the Account.